Clinical Research Directory
Browse clinical research sites, groups, and studies.
Central-boost Ablative Radiation Therapy for Solid Tumors (CBART)
Sponsor: Changhai Hospital
Summary
In the case of large tumors or tumors closely adjacent to organs at risk, ablative doses offered by stereotactic body radiation therapy (SBRT) could not be delivered. Therefore, a technique that could provide high radiation doses to tumors without increasing of risks of severe adverse effects is required.
Official title: Central-boost Ablative Radiation Therapy for Large Tumors or Tumors Adjacent to Organs at Risk
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
67
Start Date
2024-05-12
Completion Date
2026-12-31
Last Updated
2024-05-23
Healthy Volunteers
No
Conditions
Interventions
Central-boost ablative dose delivered by stereotactic body radiation therapy
An inner and complete gross tumor volume (iGTV) is created within the gross tumor volume (GTV). For the liver or lung tumor, the convetional radiation dose is 35-45Gy/5f. Regarding the pancreatic tumor or retroperitoneal tumor, the radiation dose is 30-40Gy/5f. Hence, the radiation dose of iGTV should not be less than 120% of the dose of GTV.
Locations (1)
Huojun Zhang
Shanghai, Shanghai Municipality, China